For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, CRISPR flipped to a generally accepted accounting principles (GAAP) loss of $37 million ($0.

Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $39.41, demonstrating a -0.76% swing from the preceding day's closing price. This change lagged the S&P 500's 0.67% gain on the day. At the same time,